NLS PHARMACEUTICS LTD (NLSP)
CH0523961370 - Common Stock
We assign a fundamental rating of 1 out of 10 to NLSP. NLSP was compared to 193 industry peers in the Pharmaceuticals industry. NLSP has a bad profitability rating. Also its financial health evaluation is rather negative. NLSP has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year NLSP has reported negative net income.
NLSP had a negative operating cash flow in the past year.
In the past 5 years NLSP always reported negative net income.
In the past 5 years NLSP always reported negative operating cash flow.
1.2 Ratios
NLSP's Return On Assets of -552.61% is on the low side compared to the rest of the industry. NLSP is outperformed by 96.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -552.61% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-348.14%
ROA(5y)-411.87%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NLSP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for NLSP has been reduced compared to 1 year ago.
The number of shares outstanding for NLSP has been reduced compared to 5 years ago.
The debt/assets ratio for NLSP is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -108.73, we must say that NLSP is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of NLSP (-108.73) is worse than 95.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -108.73 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 0.15 indicates that NLSP may have some problems paying its short term obligations.
With a Current ratio value of 0.15, NLSP is not doing good in the industry: 98.43% of the companies in the same industry are doing better.
A Quick Ratio of 0.15 indicates that NLSP may have some problems paying its short term obligations.
With a Quick ratio value of 0.15, NLSP is not doing good in the industry: 98.43% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.15 | ||
| Quick Ratio | 0.15 |
3. Growth
3.1 Past
NLSP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 19.12%, which is quite good.
EPS 1Y (TTM)19.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.66%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 40.37% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y89.47%
EPS Next 2Y40.37%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
NLSP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NLSP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
NLSP's earnings are expected to grow with 40.37% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.37%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for NLSP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NLS PHARMACEUTICS LTD
NASDAQ:NLSP (12/20/2024, 8:00:01 PM)
After market: 1.9 -0.05 (-2.56%)1.95
-0.43 (-18.07%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners25.87%
Inst Owner Change-99.8%
Ins Owners11.45%
Ins Owner ChangeN/A
Market Cap3.86M
Analysts43.33
Price TargetN/A
Short Float %7.26%
Short Ratio0.2
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-3900%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-6.72
EYN/A
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)-1.98
FCFYN/A
OCF(TTM)-1.98
OCFYN/A
SpS0
BVpS-4.68
TBVpS-4.68
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -552.61% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-348.14%
ROA(5y)-411.87%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.15 | ||
| Quick Ratio | 0.15 | ||
| Altman-Z | -108.73 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)133.33%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.66%
EPS Next Y89.47%
EPS Next 2Y40.37%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y56.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y69.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y69.58%
OCF growth 3YN/A
OCF growth 5YN/A